Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: Lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 855-863

  Ritland, Steve R ^a   Leighton, Jonathan A ^a   Hirsch, Rhoda Elison ^b   Morrow, Jason D ^c   Weaver, Amy L ^a   Gendler, Sandra J ^a  

^a MAYO CLINIC   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN SYNTHASE; SALAZOSULFAPYRIDINE; SULINDAC;

ADENOMATOUS POLYP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; ENTERITIS; HISTOPATHOLOGY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADENOMATOUS POLYPS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; FLUOROMETRY; INTESTINAL NEOPLASMS; MESALAMINE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PIROXICAM; SULFASALAZINE; SULINDAC;

EID: 0032945490     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Lippman, S. M., Benner, S. E., and Hong, W. K. Chemoprevention. Strategies for the control of cancer. Cancer (Phila.), 72 (Suppl. 3): 984-990, 1993.
2. Willenbucher, R. F. Inflammatory bowel disease. Semin. Gastrointest. Dis., 7: 94-104, 1996.
3. Greenstein, A. J., Sachar, D. B., Pucillo, A., Vassiliades, G., Smith, H., Kreel, I., Geller, S. A., Janowitz, H. D., and Aufses, A. H., Jr. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology, 77: 290-294, 1979.
4. Sugita, A., Sachar, D. B., Bodian, C., Ribeiro, M. B., Aufses, A. H., Jr., and Greenstein, A. J. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut, 32: 167-169, 1991.
5. Levin, B. Ulcerative colitis and colon cancer: biology and surveillance. J. Cell. Biochem., 16G (Suppl.): 47-50, 1992.
6. DuBois, R. N., Giardiello, F. M., and Smalley, W. E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. N. Am., 25: 773-791, 1996.
7. Giardiello, F. M. NSAID-induced polyp regression in familial adenomatous polyposis patients. Gastroenterol. Clin. N. Am., 25: 349-362, 1996.
8. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
9. Alberts, D. S., Hixson, L., Ahnen, D., Bogert, C., Einsphar, J., Paranka, N. Brendel, K., Gross, P. H., Pamukcu, R., and Burt, R. W. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J. Cell. Biochem., 22 (Suppl.): 18-23, 1995.
10. Rigas, B., Goldman, I. S., and Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122: 518-523, 1993.
11. Levy, G. N. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J., 11: 234-247, 1997.
12. Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Ritchie, J., Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57: 2909-2915, 1997.
13. Chiu, C. H., McEntee, M. F., and Whelan, J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res., 57: 4267-4273, 1997.
14. Simon, L. S. Actions and toxicity of nonsteroidal anti-inflammatory drugs. Curr. Opin. Rheumatol., 8: 169-175, 1996.
15. Davies, N. M. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis. Colon Rectum., 38: 1311-1321, 1995.
16. Gaginella, T. S., and Walsh, R. E. Sufasalazine. Multiplicity of action. Dig. Dis. Sci., 37: 801-812, 1992.
17. Cohen, R. D., and Hanauer, S. B. Immunomodulatory agents and other medical therapies in inflammatory bowel disease. Curr. Opin. Gastroenterol., 11: 321-330, 1995.
18. Moody, G. A., Jayanthi, V., Probert, C. S., Mac Kay, H., and Mayberry, J. F. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur. J. Gastroenterol. Hepatol., 8: 1179-1183, 1996.
19. Pinczowski, D., Ekbom, A., Baron, J., Yuen, J., and Adami, H. O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology, 107: 117-120, 1994.
20. Hixson, L., Tmjillo, A., Hansen, K., Ritchie, J., and Earnest, D. Effect of oral olsalazine sodium and parenteral aspirin on azoxymethane (AOM) induced colon neoplasia in the rat. Gastroenterology, 102: A363, 1992.
21. MacGregor, D. J. Induction of colon cancer cell apoptosis in vitro and inhibition of intestinal tumor formation in Min/+ mice by balsalazide and its metabolites. Gastroenterology, 110: A553, 1996.
22. Hixson, L. J., Alberts, D. S., Krutzsch, M., Einsphar, J., Brendel, K., Gross, P. H., Paranka, N. S., Baier, M., Emerson, S., and Pamukcu, R. Antiproliferative effect of nonsteroidal anti-inflammatory drugs against human colon cancer cells. Cancer Epidemiol. Biomark. Prev., 3: 433-438, 1994.
23. D'Argenio, G., Cosenza, V., Delle Cave, M., Iovino, P., Delle Valle, N., Lombardi, G., and Mazzacca, G. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. Gastroenterology, 110: 1727-1734, 1996.
24. Davis, A. E., Patterson, F., and Crouch, R. The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. Br. J. Cancer, 66: 777-780, 1992.
25. Greenfield, S. M., Punchard, N. A., Teare, J. P., and Thompson, R. P. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment. Pharmacol. Ther., 7: 369-383, 1993.
26. Moser, A. R., Pilot, H. C., and Dove, W. F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science (Washington DC), 247: 322-324, 1990.
27. Su, L. K., Kinzler, K. W., Vogelstein, B., Preisinger, A. C., Moser, A. R., Luongo, C., Gould, K. A., and Dove, W. F. Multiple intestinal neoplasia caused by a mutation in the murine homologue of the APC gene. Science (Washington DC), 256: 668-670, 1992.
28. Shoemaker, A. R., Gould, K. A., Luongo, C., Moser, A. R., and Dove, W. F. Studies of neoplasia in the Min mouse. Biochim. Biophys. Acta., 1332: F25-F48, 1997.
29. Bansal, P., and Sonnenberg, A. Risk factors of colorectal cancer in inflammatory bowel disease. Am. J. Gastroenterol., 91: 44-48, 1996.
30. Kern, S. E., Redston, M., Seymour, A. B., Caldas, C., Powell, S. M., Komacki, S., and Kinzler, K. W. Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology, 107: 420-428, 1994.
31. Tarmin, L., Yin, J., Harpaz, N., Kozam, M., Noordzij, J., Antonio, L. B., Jiang, H. Y., Chan, O., Cymes, K., and Meltzer, S. J. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res., 55: 2035-2038, 1995.
32. Dove, W. F., Gould, K. A., Luongo, C., Moser, A. R., and Shoemaker, A. R. Emergent issues in the genetics of intestinal neoplasia. Cancer Surv., 25: 335-355, 1995.
33. Jacoby, R. F., Marshall, D. J., Newton, M. A., Novakovic, K., Tutsch, K. Cole, C. E., Lubet, R. A., Kelloff, G. J., Verma, A., Moser, A. R., and Dove, W. F. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res., 56: 710-714, 1996.
34. Reddy, B. S., Rao, C. V., and Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res., 56: 4566-4569, 1996.
35. Rao, C. V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V., and Reddy, B. S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55: 1464-1472, 1995.
36. Hirsch, R. E., Lin, M. J., and Das, K. M. Estimation of 5-amino-salicylic acid and its metabolite in human serum by front-face fluorometry: a simple and sensitive method. J. Lab. Clin. Med., 116: 45-50, 1990.
37. Dubois, R. N., Awad, J., Morrow, J., Roberts, L. J., and Bishop, P. R. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor alpha and phorbol ester. J. Clin. Invest., 93: 493-498, 1994.
38. Hioki, K., Shivapurkar, N., Oshima, H., Alabaster, O., Oshima, M., and Taketo, M. M. Suppression of intestinal polyp development by low-fat and high-fiber diet in Apc (δ716) knockout mice. Carcinogenesis (Lond.), 10: 1863-1865, 1997.
39. Baribault, H., Penner, J., Iozzo, R. V., and Wilson-Heiner, M. Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice. Genes Dev., 8: 2964-2973, 1994.
40. Hermiston, M. L., and Gordon, J. I. Inflammatory bowel disease and adenomas in mice expresssing a dominant negative N-cadherin. Science (Washington DC), 270: 1203-1207, 1995.
41. Rudolph, U., Finegold, M. J., Rich, S. S., Harriman, G. R., Srinivasan, Y., Brabet, P., Boulay, G., Bradley, A., and Birnbaumer, L. Ulcerative colitis and adenocarcinoma of the colon in Gai2-deficient mice. Nat. Genet., 10: 143-150, 1995.
42. Williams, C. S., Luongo, C., Radhika, A., Zhang, T., Lamps, L. W., Nanney, L. B., Beauchamp, R. D., and DuBois, R. N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 111: 1134-1140, 1996.
43. Prescott, S. M., and White, R. L. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell. 87: 783-786, 1996.
44. Shafii, A., Chowdury, J. R., and Das, K. M. Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats. Am. J. Gastroenterol., 77: 297-299, 1982.
45. Yu, D. K., Elvin, A. T., Morill, B., Eichmeier, L. S., Lanman, R. C., and Giesing, D. H. Pharmacokinetics of Pentasa capsules in man. Pharmacol. Res., 8: S315, 1991.
46. Beeken, W., Howard, D., Bigelow, J., Trainer, T., Roy, M., Thayer, W., and Wild, G. Controlled trial of 4-ASA in ulcerative colitis. Dig. Dis. Sci., 42: 354-358, 1997.
47. Bilyard, K. G., Joseph, E. C., and Metcalf, R. Mesalazine: an overview of key preclinical studies. Scand. J. Gastroenterol , 172 (Suppl.): 52-55, 1990.
48. Zijlstra, F. J., van Dijk, A. P., Ouwendijk, R. J., van Riemsdijk-Overbeeke, I. C., and Wilson, J. H. Eicosanoid production by the mucosa in inflammatory bowel disease after 5-ASA treatment. Agents Actions, 38: C122-C124, 1993.
49. Peskar, B. M., Dreyling, K. W., May, B., Schaarschmidt, K., and Goebell, H. Possible mode of action of 5-aminosalicylic acid. Dig. Dis. Sci., 32(Suppl. 12): 51S-56S, 1987.
50. Sartor, R. B. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am. J. Gastroenterol., 92(Suppl. 12): 5S-11S, 1997.
51. Greenfield, S. M., Boswell, D. J., Punchard, N. A., and Thompson, R. P. The effects of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid on lipid peroxidation in erythrocytes and prostaglandin production by mononuclear cells. Aliment. Pharmacol. Ther., 6: 671-683, 1992.